Impact of estrogen receptor (ER) and human epidermal growth factor receptor-2 (HER2) co-expression on breast cancer disease characteristics: implications for tumor biology and research (Q44541840)

From Wikidata

Jump to navigation Jump to search

scientific article published on 26 September 2014

Language	Label	Description	Also known as
English	Impact of estrogen receptor (ER) and human epidermal growth factor receptor-2 (HER2) co-expression on breast cancer disease characteristics: implications for tumor biology and research	scientific article published on 26 September 2014

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Impact of estrogen receptor (ER) and human epidermal growth factor receptor-2 (HER2) co-expression on breast cancer disease characteristics: implications for tumor biology and research (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

author name string

Abeer Alqaisi

1

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Li Chen

2

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Edward Romond

3

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Mara Chambers

4

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Mark Stevens

5

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Grace Pasley

6

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Mukta Awasthi

7

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Suleiman Massarweh

8

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

language of work or name

0 references

publication date

26 September 2014

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Breast Cancer Research and Treatment

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

148

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

437-444

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3145-X

21 January 2018

Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3145-X

21 January 2018

US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3145-X

21 January 2018

A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3145-X

21 January 2018

Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3145-X

21 January 2018

Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3145-X

21 January 2018

Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3145-X

21 January 2018

Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3145-X

21 January 2018

Molecular portraits of human breast tumours

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3145-X

21 January 2018

The genomic landscape of breast cancer as a therapeutic roadmap

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3145-X

21 January 2018

Comprehensive molecular portraits of human breast tumours

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3145-X

21 January 2018

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3145-X

21 January 2018

Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3145-X

21 January 2018

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3145-X

21 January 2018

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3145-X

21 January 2018

Trastuzumab emtansine for HER2-positive advanced breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3145-X

21 January 2018

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3145-X

21 January 2018

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3145-X

21 January 2018

Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes?

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3145-X

21 January 2018

Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3145-X

21 January 2018

Her2/neu expression predicts the response to antiaromatase neoadjuvant therapy in primary breast cancer: subgroup analysis from celecoxib antiaromatase neoadjuvant trial

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3145-X

21 January 2018

Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3145-X

21 January 2018

Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3145-X

21 January 2018

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3145-X

21 January 2018

Even low-level HER2 expression may be associated with worse outcome in node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3145-X

21 January 2018

Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3145-X

21 January 2018

Quantitative ER and PgR assessment as predictors of benefit from lapatinib in postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3145-X

21 January 2018

Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3145-X

21 January 2018

Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-related

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3145-X

21 January 2018

Her-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3145-X

21 January 2018

HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3145-X

21 January 2018

Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3145-X

21 January 2018

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update

1 reference

https://api.crossref.org/works/10.1007%2FS10549-014-3145-X

21 January 2018

Identifiers

10.1007/S10549-014-3145-X

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44541840&oldid=2206726250"